Beneficial effects of parenteral GLP-1 delivery by cell therapy in insulin-deficient streptozotocin diabetic mice

S Vasu, RC Moffett, Janie McCluskey, MH Hamid, Nigel Irwin, Peter Flatt

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Parenteral delivery of long-acting glucagon-like peptide-1 (GLP-1) mimetics has received much attention as a therapeutic option for diabetes. However, cell therapy-based GLP-1 treatments may provide a more physiological regulation of blood glucose. The present study assessed the effects of chronic GLP-1 delivery by cell therapy, using the GLP-1-secreting GLUTag cell line, in normoglycemic and streptozotocin-induced diabetic mice. GLUTag cell aggregates were transplanted into the subscapular region of mice. Over 30 days, cellular transplantation gave rise to encapsulated and well-vascularized growths, which contained immunoreactive GLP-1. Cell implantation was well tolerated and had no appreciable metabolic effects in normal mice. However, transplantation significantly (P
Original languageEnglish
Pages (from-to)1077-1084
JournalGene Therapy
Volume20
Issue number11
DOIs
Publication statusPublished - 1 Nov 2013

Fingerprint Dive into the research topics of 'Beneficial effects of parenteral GLP-1 delivery by cell therapy in insulin-deficient streptozotocin diabetic mice'. Together they form a unique fingerprint.

  • Cite this